Vice President, Global Program Leader

OverviewJoin to apply for the Vice President, Global Program Leader role at Kura Oncology, Inc.Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.Essential Job FunctionAct as the “CEO” for Kura’s lead menin inhibitor, ziftomenib, fostering a sense of mission, creativity and urgency.Lead the Global Program Team: an empowered multi-disciplinary team of leadersDevelop near and long-term strategic objectives and recommendations for the asset across all indications from early to late-stage development and ongoing lifecycle managementAccountable - the single point of accountability for all Global Program Team activitiesDefine and lead the membership of the core and extended teamFocus on full cross-functional business including clinical development, commercial, CMC, finance, and business developmentExtended partnership with global program management, commercial and development functional leads, external partners, and Senior Leadership TeamWork with the team and with senior leaders to define the strategic direction for the asset and plays a key role, driving execution of asset goals, and ensuring alignment and integration among Core Global Program Team and Extended Teams.Form a close partnership with department leads and with program management to build program plans, identify and mitigate risks, capitalize on asset opportunities, manage budgets, and timelines and ensure best practices.Represent the program to internal and external stakeholders, including collaboration partners and the Board of Directors.Lead key program team meetings and serve as a point of escalation for the program to senior leadership.Help build best practices for efficient and effective program teams.Support external stakeholders engagement including Health Authorities, potential strategic partners, vendors and KOLs.Drive cross-functional collaboration and act as the owner of the Asset Integrated Development PlanWork with corporate affairs on investor communications to optimize external program communicationsPartner directly with the SVP, Global Program Leadership to lead change and evolution of program and portfolio strategy to enhance decision-making, build high-performing teams, and optimize portfolio decisions across programsJob Specifications15+ years drug development and commercialization experience10+ years oncology experience, with preference in heme/oncologyPrior experience with partnered programs (development and/or commercial) will be valuableHighly visible role focused on cross-functional team leadership, including strategy development, communication and driving tactical delivery of programsStrategy, Project, Program and Portfolio Management, Talent Development, Mentorship and Alliance Management expertiseAdvanced Degree (MBA, MS, PharmD, PhD)Build trust, transparency, and clear communication plansConnect strategic vision for asset strategy to the competitive environment and company strategyAbility to understand and communicate complex scientific and commercial matters while keeping the big picture in mind and the credibility to engage subject matter experts on details at all levels in the organizationAbility to consider and integrate different points of view, new ideas etc.; demonstrates self-awareness and emotional intelligenceThorough understanding of company specific matrix organization, functional impact and regional representation to proactively build the relationships needed to be successful across functions and departmentsCompensation and BenefitsThe base range for a Vice President is $333,000 - $368,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.Kura’s Values that are used for candidate selection and performance assessments:We work as one for patientsWe are goal-focused and deliver with excellenceWe are science-driven courageous innovatorsWe strive to bring out the best in each other and ourselvesKura PackageCareer advancement/ development opportunitiesCompetitive comp packageBonus401K + Employer contributionsGenerous stock optionsESPP Plan20 days of PTO to start18 Holidays (Including Summer & Winter Break)Generous Benefits Package with a substantial employer matchPaid Paternity/Maternity LeaveIn-Office Catered lunchesHome Office SetupLifestyle Spending StipendCommuter Stipend (Boston Office)Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much moreKura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.If you are a California resident, please see the attached Privacy Notice CA Privacy NoticeSeniority levelExecutiveEmployment typeFull-timeJob functionProject Management and Information TechnologyThis description reflects the essential nature of the position. It does not restrict management from assigning other duties as necessary to fulfill the role. #J-18808-Ljbffr